Ramucirumab is for the treatment of hepatocellular carcinoma in patients with an alpha-fetoprotein level of 400 ng/mL or higher.
FDA Approvals
FDA Approves First Biomarker-Driven Drug for HCC
Ramucirumab is for the treatment of hepatocellular carcinoma in patients with an alpha-fetoprotein level of 400 ng/mL or higher.
FDA Approvals
